Activity Release and Expiration dates
Course Number: CME 07NSAM
Release date: September 17, 2007 valid through September 17, 2008.
 
Target Audience
Urologists/Nurses
 
Needs Statement

Urologists need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. The results of the 2005 and 2006 AUA Annual Meeting attendee surveys revealed that a revolution is occurring in medicine with the rapidly expanding use of minimally invasive surgical techniques, including laparoscopy and robotics. These new technologies offer the potential promise of less morbid operative courses with lessened recovery times. As with any revolution, however, there are problems that need to be addressed and overcome. One of these is the issue of training of both residents and practicing urologists in these areas. The 2007 Section meeting will feature a total of 9 papers, a one-hour presentation, and a half hour lecture to discuss educational initiatives that address this problem.

Another area of urology that is exploding is the area of female pelvic medicine and reconstructive surgery. With the aging population, the number of women that will develop bothersome urinary incontinence and other pelvic issues (e.g. vaginal prolapse) is increasing dramatically. Several of the problems associated with female pelvic disease will be addressed at the 2007 meeting, including overactive bladder, urodynamic studies and an update on surgery for female incontinence and vaginal reconstruction.

Prostate cancer remains one of the most common cancers in men. Active urologist members of AUA continue to report prostate cancer as the number one area of interest. Our knowledge of this disease is growing rapidly, including improved understanding of the initiating factors, the usefulness of screening, ways to determine those cancers that pose a significant threat to the patient, and ways to potentially prevent the development of clinical prostate cancer and advanced stage disease. The 2007 plenary sessions will include 16 related papers and two guest lectures on topics relating to bone health of prostate cancer patients, genetics of urologic cancers, chemotherapy, and prostate cancer expectant management.

This meeting will also feature additional podium sessions including presentations on impotence/infertility, benign prostatic hyperplasia (BPH)/neurology, and erectile dysfunction. The meeting offers a maximum of 6.5 AMA PRA Category 1 creditsTM.

Overall, the State-of-the-Art lectures, podium and poster sessions presented by many of AUA's experts promise to deliver excellent educational value in the expanding world of urology. New at this year's meeting is a half-day AUA Coding Course to update attendees on medicare changes, new ICD-9 and CPT Codes and evaluation and management services.
 
Specific Learning Objectives

At the conclusion of the 2007 Annual Meeting, participants should be able to:

  • Describe recent developments in the medical and surgical management of urology patients;
  • Identify new technologies for the treatment of urologic problems;
  • Outline various male mental health disorders as they pertain to sexual health and discuss therapy;
  • Analyze the potential threats to urologic practice and specify possible solutions.
 
Topics and Educational Content
  1. Bladder cancer
  2. Erectile dysfunction
  3. Female Incontinence
  4. General Oncology
  5. Male Void Dysfunction
  6. Renal Cell Cancer
  7. Bone Health
  8. Obesity
  9. Infertility
  10. Impotence
  11. Infertility
  12. Endourology
  13. Laparoscopy
  14. Kidney cancer
  15. Pediatric urology
  16. Prostate cancer
  17. Prostatitis
  18. Urinary incontinence
 
Implementation and Method of Physician Participation in the Learning Process

There is no charge to view the educational material. The estimated time for completion of this class is 1.9 hours.

Follow these steps to complete the class:

  • View the video and slide presentation.
  • Take the online test and complete the online evaluation.
  • Review your test answers before submitting.
  • Receive a passing score of 70% or higher.
  • Discuss the information covered with your staff or colleagues.
American Disabilities Act Statement: For accommodations on the basis of disability, call: +34 93 459 2220.
The American Urological Association is an Equal Opportunity Institution.
 
Programme Committee
  • Ronald P. Kaufman, M.D., Chair
    Urological Institute of Northeastern New York
  • Timothy D. Averch, M.D.
    University of Pittsburgh
  • Serge Carrier, M.D.
    McGill University
  • Elise J. Billings De, M.D.
    Albany Medical Center Urology
  • Robert A. Mevorach, M.D.
    University of Rochester Medical Center
  • Imad S. Nsouli, M.D.
    VA Medical Center
  • D. Robert Siemens
    Kingston General Hospital
 
Faculty Speaker Disclosure

Northeastern Section Annual Meeting
September, 5 – 9, 2007
Rochester, New York, USA

The AUA must ensure balance, independence, objectivity, and scientific rigor in all its individually jointly sponsored educational activities. All individuals participating in any education sponsored activity are expected to disclose any off-label or investigational uses mentioned in their presentations, as well as all financial interests and/or other relationships with all manufacturer(s) of product(s) and/or provider(s) of services, including alternative treatment technologies. (Financial interests or other relationships can include such things as grants or research support, employee consultant, major stockholder member of Speakers Bureau, etc.) The intent of this disclosure is not to prevent an individual with a financial or other relationship with provider(s) or manufacturer(s) from participation, but rather to provide the audience and listeners with information regarding such relationships from which the audience and listeners can make a judgment. It remains for the listener to determine whether the presenters' interests or relationships influence the presentation with regard to exposition or conclusion.

Listed below are the faculty who have disclosed (a) relationship(s) with industry:
Indicates Affirmation

CME Organizer
Corkin, Heather None
   
CME Presenter
Author Disclosure
Amin, Moamen M. None
Amling, Chris Sanofi-Aventis, Meeting Participant/Lecturer; TAP Pharmaceuticals, Meeting Participant/Lecturer
Appell, Rodney A. American Medical Systems, Commercial Entity,Consultant; Boston Scientific, Commercial Entity,Instructor, Consultant; American Medical Systems, Commercial Entity, Stockholder; Novasys Medical, Commercial Entity, Grant support
Bagli, Darius Jehan None
Bauer, Ross None
Belarmino, James M. None
Bogaert, Guy None
Braga, Luis H. None
Capello, Seth A. None
Carson, Cully

Auxilium Pharmaceuticals, Inc., Consultant/Advisor, Meeting Participant/Lecturer, Scientific Study/Trial; Solvay Pharmaceuticals, Inc., Consultant/Advisor, Meeting Participant/Lecturer

Carter, Balentine H. Gen-Probe, Investigator
Chin, Joseph L. None
Chughtai, Bilal None
Cline, Kevin J. Novasys Medical, Commercial Entity, Grant support
Conners, William P. None
Corcoran, Anthony T. None
Dineen, Martin K. Endocare, Commercial Entity, Honoraria
Domes, Trustin None
Feifer, Andrew None
Gibbons, Erin P. None
Gill, Inderbir Singh None
Glinianski, Michal None
Golijanin, Dragan None
Hayn, Matthew H. None
He, Xiangrong None
Jenkins, Lawrence None
Johnston, Paul H. None
Joseph, Jean V. Pfizer, Speaker's Bureau; Intuitive Surgical, Proctor; Eli Lilly, Speaker's Bureau
Kalorin, Carmin None
Kim, Hyung L. None
Knopf, Joy K. None
Krupski, Tracey L. Amgen, Consultant/Advisor
Lim, Darwin L. None
Linehan, William Marston None
MacDiarmid, Scott Esprit Pharma, Commercial Entity,Consultant; Ortho-McNeil, Commercial Entity,Consultant; Novartis, Commercial Entity,Consultant; Watson, Commercial Entity,Consultant; Pfizer, Commercial Entity,Consultant; Esprit Pharma, Commercial Entity,Other; Ortho-McNeil
MacLellan, Dawn L. None
Maier, John None
Manyak, Michael J. Cytogen Corporation, Commercial Entity, Employee
Maranchie, Jodi K. None
Mayer, Robert None
McCullough, Andrew R. Pfizer Inc, Commercial Entity,Grant support ; Pfizer Inc, Commercial Entity,Honoraria ; Pfizer Inc, Commercial Entity,Other
McVary, Kevin Pfizer, Investigator; Sanofi, Meeting Participant/Lecturer; Lilly/ICOS, Scientific Study/Trial; GSK, Scientific Study/Trial; NIDDK, Scientific Study/Trial
Morrisroe, Shelby N. None
Nickel, J. Curtis Glaxo Smith Kline (Canada), Consultant/Advisor; MERCK FROSST Canada, Consultant/Advisor, Scientific Study/Trial; Farr Laboratories, Consultant/Advisor; Triton Pharma, Consultant/Advisor; Boston Scientific, Consultant/Advisor; Sanofi-Aventis, Investigator
Orovan, William None
Patrick, Allan B. None
Petrylak, Dan P. Dendreon Corporation, Consultant/Advisor, Investigator; GBC Biotech, Consultant/Advisor, Investigator
Psooy, Karen J. None
Ray, A. Andrew None
Schellhammer, Paul F. Dendreon Corporation, Consultant/Advisor, Scientific Study/Trial, Investigator, Owner; ContraVac, Owner; AstraZeneca, Scientific Study/Trial; Soutwest Oncology Group, Scientific Study/Trial
Shabsigh, Ridwan Pfizer, Consultant/Advisor, Meeting Participant/Lecturer; Bayer/GSK/Scheing Plough, Consultant/Advisor, Meeting Participant/Lecturer; Indevus Pharmaceuticals, Consultant/Advisor; Johnson & Johnson, Consultant/Advisor; American Medical Systems, Consultant
Shingleton, William Bruce None
Siemens, D. Robert None
Singer, Eirc A. None
Smaldone, Marc C. None
Sternberg, Kevan None
Stockton, Benjamin R. None
Thornburg, Loralei L. None
Vasavada, Sandip Novartis, Consultant/Advisor; NDI Medical LLC, Investment Interest; Pfizer, Meeting Participant/Lecturer; Allergen, Scientific Study/Trial
Wilbur, Scott None
Wood, Ronald W. None
Zabinski, Andrew T. None
   
Program Planning Committee
Kaufman, Ronald Glaxo Klein Smith, Investigator, Meeting Participant/Lecturer
Averch, Timothy D. Bard Urologic, Consultant/Advisor
Carrier, Serge

Pfizer Canada, Board Member, Officer, Trustee; Bayer Canada, Board Member, Officer, Trustee; Solvay Canada, Board Member, Officer, Trustee; Eli Lilly Canada, Board Member, Officer, Trustee

De, Elise J. Billings None
Mevorach, Robert A. None
Nsouli, Imad S. None
Razvi, Hassan Cook Urologic, Scientific Study/Trial; GYRUS ACMI, Scientific Study/Trial; Allergan, Scientific Study/Trial
Siemens, D. Robert None
Annette Stork TTMed International Product Manager, Prous Science
Barbara L. Jones
Medical Writer
   
Accreditation Statement

The AUA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The AUA designates this educational activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Academy of Physicians Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by the ACCME.
 
Conflict Resolution Statement
The AUA, Office of Continuing Medical Education has reviewed this activity's speaker and planner disclosure(s) and has resolved all identified conflicts of interest, if applicable.
 
Disclosure Policy
It is the policy of the AUA to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in these programs are expected to disclose to the program audiences any real or apparent conflict of interest related to the content of their presentation.
 
Disclosure Information
The AUA has adopted a policy regarding disclosure affecting continuing medical education programs. Program faculty is asked to disclose any affiliations or financial interests they may have in any organization that may have an interest in their comments.
 
Commercial Support
This program is funded by an educational grant from Astellas Pharma US, Inc.
 
Acknowledgments
This presentation was videotaped during the Northeastern Section Annual Meeting, Rochester, New York.
A special thanks to Prous Science, S.A. for videotaping this presentation.

 

 
Webcast produced by Prous Science
© Prous Science 2007.